Scholarlink

Background <p>Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment.</p> Aims <p>This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions.</p> Methods <p>HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy–Lymphoma (FACT-Lym) in a prospective, multicenter observational study on rituximab safety across Italian hematology units (March 2018–June 2022).</p> Results <p>Of 772 patients with Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL), 412 (62.6%) completed the HRQoL assessment. Overall, patients reported acceptable quality of life. Key concerns included reduced enjoyment of life (45.1%), poor sleep (42.0%), and dissatisfaction with quality of life (41.0%). Functional impairments and emotional distress were also reported. CLL patients showed slightly better physical and lymphoma-specific well-being than NHL patients. Patients with other hematologic diseases had lower scores across several domains.</p> Conclusions <p>While HRQoL is generally acceptable in NHL and CLL, functional well-being is most impacted. Routine integration of HRQoL assessments is essential to identify unmet needs and support patient-centered care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study

  • 期刊论文

  • 发表日期：

    2026年3月1日

查看全文
  • Silvana A. M. Urru,
  • Flavia Mayer,
  • Stefania Spila Alegiani,
  • Francesca Paoloni,
  • Anna Guella,
  • Roberta Murru,
  • Giampaolo Bucaneve,
  • Giulio Formoso,
  • Vito Racanelli,
  • Anna Forti,
  • Claudio Fozza,
  • Giuseppe Longo,
  • Chiara Fulgenzio,
  • Felice Musicco,
  • Annalisa Campomori

摘要

Background

Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment.

Aims

This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions.

Methods

HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy–Lymphoma (FACT-Lym) in a prospective, multicenter observational study on rituximab safety across Italian hematology units (March 2018–June 2022).

Results

Of 772 patients with Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL), 412 (62.6%) completed the HRQoL assessment. Overall, patients reported acceptable quality of life. Key concerns included reduced enjoyment of life (45.1%), poor sleep (42.0%), and dissatisfaction with quality of life (41.0%). Functional impairments and emotional distress were also reported. CLL patients showed slightly better physical and lymphoma-specific well-being than NHL patients. Patients with other hematologic diseases had lower scores across several domains.

Conclusions

While HRQoL is generally acceptable in NHL and CLL, functional well-being is most impacted. Routine integration of HRQoL assessments is essential to identify unmet needs and support patient-centered care.